QV Bioelectronics
Electric field implants for brain cancer
Liverpool, UK
QV Bioelectronics focuses on therapeutic devices.
How We Help
Problem Statement
Aggressive brain cancers, such as glioblastoma (GBM) and diffuse midline glioma (DMG), have very low survival rates and limited effective treatment options.
Core Technology
Implantable Bioelectronics
Key Differentiators
Developing the GRACE implant for treating aggressive brain cancers.
Clinical Focus
Oncology; Neurosurgery
Company Info
- Business Model
- Hardware
- Total Funding
- 9,630,000
- Website
- qvbio.co.uk/
Categories
Technologies
Clinical & IP
Clinical Validation
Breakthrough pre-clinical safety/efficacy results in large animal studies. FDA Breakthrough Device Designation. Positive FDA pre-submission feedback. First-in-human trials planned 2026. Published preclinical data: 3-month safety with no significant adverse events.
MedStartr Index Score
?What do you think of QV Bioelectronics?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.